Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme
Sheng-Hua Chu1, Yan-Bin Ma, Dong-Fu Feng
1Department of Neurosurgery, No. 3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201900, PR China. shenghuachu@126.com
Molecular Medicine Reports
|October 19, 2012
Summary
High expression of SATB1 and Bcl-2 in glioblastoma multiforme (GBM) correlates with poor prognosis. Co-assessment of SATB1 and Bcl-2 may aid GBM diagnosis and therapy.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Special AT-rich sequence-binding protein-1 (SATB1) is overexpressed in various human cancers.
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with complex molecular underpinnings.
Purpose of the Study:
- To investigate the correlation between SATB1 and B-cell lymphoma 2 (Bcl-2) expression in GBM.
- To determine the clinical significance of SATB1 and Bcl-2 co-expression in GBM patient survival.
Main Methods:
- Analysis of 70 GBM samples and 10 normal brain tissues.
- Detection of SATB1 mRNA via in situ hybridization.
- Immunohistochemistry for Bcl-2 and PCNA protein expression.
- Flow cytometry for apoptosis assessment.
Main Results:
- SATB1 mRNA and Bcl-2 protein levels were significantly elevated in GBM compared to normal brain tissue.
- Higher SATB1 and Bcl-2 levels correlated with poorer patient survival.
- Positive correlations were found between SATB1 and Bcl-2, SATB1 and PCNA, and Bcl-2 and PCNA.
- Negative correlations were observed between SATB1 and apoptosis, and Bcl-2 and apoptosis.
Conclusions:
- SATB1 and Bcl-2 are significantly overexpressed in GBM and are associated with poor prognosis.
- Co-expression of SATB1 and Bcl-2 may serve as a valuable prognostic biomarker for GBM.
- Further assessment of SATB1 and Bcl-2 could inform GBM diagnosis and therapeutic strategies.
